GlassScriptPhysician profile
Roxanne J Abitbol
NPI 1841415197
$9,181.65
in general payments reported to CMS, 2019-2025
28 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $531 · 2021: $331 · 2022: $967 · 2023: $1,699 · 2024: $2,420 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,339.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,584.98 | 2019-2025 | |
| Janssen Biotech, INC. | $1,208.86 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $968.54 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Lilly USA, LLC | $711.52 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $601.31 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $486.84 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $483.74 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $392.10 | 2019-2025 | Absorica Ld, Winlevi |
| Incyte Corporation | $389.17 | 2022-2025 | Opzelura |
| Amgen INC. | $375.30 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $315.11 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $314.01 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $296.70 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $219.69 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $162.96 | 2019-2024 | Cabtreo, Jublia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $112.90 | 2025 | Nemluvio |
| Dermira, INC. | $76.33 | 2019-2020 | |
| Allergan, INC. | $72.71 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2020 | |
| Botanix Sb INC | $64.29 | 2025 | Sofdra |
| Ucb, INC. | $60.60 | 2019-2025 | Bimzelx |
| Almirall LLC | $45.43 | 2019-2023 | Klisyri |
| Kyowa Kirin, INC. | $41.76 | 2022-2023 | Poteligeo |
| Epi Health, LLC | $39.79 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $27.33 | 2019-2020 | |
| Krystal Biotech INC | $20.82 | 2023 | Vyjuvek |
| Organon LLC | $18.55 | 2025 | |
| Verrica Pharmaceuticals INC. | $18.31 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Abitbol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.